Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03185039 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents

Study acronym: MMP-REIN
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 11 words
    • Publications: details revised at 4 of 4 entries
  2. Primary and study completion dates: Dec 13, 2022 to Dec 19, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. Primary and study completion dates: Nov 29, 2020 to Dec 13, 2022v3
  4. Primary endpoints revised (2)
    • Study description revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective research of Matrix Metalloproteinases (MMP) 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents (Sunitinib or Pazopanib).
Trial Details
NCT Number NCT03185039
Lead Sponsor Institut Paoli-Calmettes
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Kidney Cancer
Related terms Kidney Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov